ArticleInternational journal of women's health2010
Emergency contraception: potential role of ulipristal acetate.
Article in International journal of women's health, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 44 citations in OpenAlex.
- First report on electrochemical sensing of ulipristal acetate in pharmaceutical formulations and biological fluids using reduced graphene oxide-CuO nanohybrid based sensors.BMC chemistry · 2026Article
- Review
- Targeting progesterone signaling prevents metastatic ovarian cancer.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor.The Journal of clinical endocrinology and metabolism · 2020Article
- Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids.Biology of reproduction · 2017Review
- Association between knowledge about levonorgestrel emergency contraception and the risk of ectopic pregnancy following levonorgestrel emergency contraception failure: a comparative survey.Pharmacoepidemiology and drug safety · 2016Article
- Mechanism of Action of Ulipristal Acetate for Emergency Contraception: A Systematic Review.Frontiers in pharmacology · 2015Review
- Ulipristal blocks ovulation by inhibiting progesterone receptor-dependent pathways intrinsic to the ovary.Reproductive sciences (Thousand Oaks, Calif.) · 2013Article
- Emerging options for emergency contraception.Clinical medicine insights. Reproductive health · 2013Review
- The Prescription of the Morning-After Pill in a Berlin Emergency Department Over a Four-Year Period - User Profiles and Reasons for Use.Geburtshilfe und Frauenheilkunde · 2012Article
- Ulipristal acetate, a progesterone receptor modulator for emergency contraception.Journal of pharmacology & pharmacotherapeutics · 2012Article
- Emergency contraception: an updated review.Translational medicine @ UniSa · 2011Article
- Ulipristal Acetate (ella): A Selective Progesterone Receptor Modulator For Emergency Contraception.P & T : a peer-reviewed journal for formulary management · 2011Article
- Review
- Immunopharmacology of ulipristal as an emergency contraceptive.International journal of women's health · 2011Article
- The state-of-the-art of emergency contraception with the cutting edge drug.German medical science : GMS e-journal · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unintended pregnancy is a global reproductive health problem. Emergency contraception (EC) provides women with a safe means of preventing unwanted pregnancies after having unprotected intercourse. While 1.5 mg of levonorgestrel (LNG) as a single dose or in 2 doses with 12 hours apart is the currently gold standard EC regimen, a single dose of 30 mg ulipristal acetate (UPA) has recently been proposed for EC use up to 120 hours of unprotected intercourse with similar side effect profiles as LNG. The main mechanism of action of both LNG and UPA for EC is delaying or inhibiting ovulation. However, the 'window of effect' for LNG EC seems to be rather narrow, beginning after selection of the dominant follicular and ending when luteinizing hormone peak begins to rise, whereas UPA appears to have a direct inhibitory effect on follicular rupture which allows it to be also effective even when administered shortly before ovulation, a time period when use of LNG is no longer effective. These experimental findings are in line with results from a series of clinical trials conducted recently which demonstrate that UPA seems to have higher EC efficacy compared to LNG. This review summarizes some of the data available on UPA used after unprotected intercourse with the purpose to provide evidence that UPA, a new type of second-generation progesterone receptor modulator, represents a new evolutionary step in EC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.